Infographic: Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: ALTAIR study

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-09-19 DOI:10.1038/s41433-024-03336-2

Ishani Barai, Rashmi G. Mathew, Sobha Sivaprasad, Christin Henein

引用次数: 0

Abstract

Reference to original article:

Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173-1187.

Abstract Image

查看原文本刊更多论文

信息图：玻璃体内阿弗利百普治疗和延长方案在渗出性年龄相关性黄斑变性中的疗效和安全性：ALTAIR研究

原文参考：Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators.玻璃体内阿弗利百普治疗和延长方案对渗出性年龄相关性黄斑变性的疗效和安全性：ALTAIR：一项随机对照试验的 52 周和 96 周结果。Adv Ther.2020年3月；37（3）：1173-1187。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464